Physician profile
Ashley David
NPI 1144777848
$1,037.74
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,038.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.46 | 2021 | |
| Novo Nordisk INC | $119.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.73 | 2021 | |
| Merck Sharp & Dohme LLC | $67.37 | 2021 | |
| Adlon Therapeutics L.P. | $65.41 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $58.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $52.60 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $43.40 | 2021 | |
| Amarin Pharma, INC. | $35.59 | 2021 | |
| Amgen INC. | $25.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.63 | 2021 | |
| Daiichi Sankyo INC. | $23.40 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.48 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.31 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.21 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.26 | 2021 | |
| Orexo US, INC. | $12.04 | 2021 | |
| Genentech USA, INC. | $3.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.